Details of the Drug

General Information of Drug (ID: DMSYRBX)

Drug Name
Atazanavir
Synonyms
198904-31-3; Latazanavir; Zrivada; Reyataz; BMS-232632; BMS 232632; Atazanavir [INN:BAN]; CGP 73547; Atazanavir Base; UNII-QZU4H47A3S; CGP-73547; HSDB 7339; Reyataz (TN); ATV; QZU4H47A3S; CHEMBL1163; CHEBI:37924; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; NCGC00182552-01; AK174307; DSSTox_CID_28617; DSSTox_RID_82887; DSSTox_GSID_48691; DR7; atazanavirum; ATZ; Atazanavirum; Atazanavir (INN); Reyataz, BMS-232632, Atazanavir; Reyataz(TM) (*1:1 sulfate*); Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI-TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2-YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1-YL]CARBAMATE; Methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Therapeutic Class
Anti-HIV Agents
Affected Organisms
Human Immunodeficiency Virus
ATC Code
J05AE08: Atazanavir
J05AE: Protease inhibitors
J05A: DIRECT ACTING ANTIVIRALS
J05: ANTIVIRALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 704.9
Logarithm of the Partition Coefficient (xlogp) 5.6
Rotatable Bond Count (rotbonds) 18
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
64% of drug becomes completely available to its intended biological destination(s) [3]
Elimination
7% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 hours [4]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.1069 micromolar/kg/day [5]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Bone marrow toxicity rs3064744 UGT1A1 OTH1C8OJ [6]
Chemical Identifiers
Formula
C38H52N6O7
IUPAC Name
methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
Canonical SMILES
CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC
InChI
InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
InChIKey
AXRYRYVKAWYZBR-GASGPIRDSA-N
Cross-matching ID
PubChem CID
148192
ChEBI ID
CHEBI:37924
CAS Number
198904-31-3
UNII
QZU4H47A3S
DrugBank ID
DB01072
TTD ID
D07IQS
VARIDT ID
DR00413
INTEDE ID
DR0150
ACDINA ID
D00047
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Protease (HIV PR) TT5FNQT POL_HV1B1 Modulator [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [9]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [8]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aflatoxin B1 aldehyde reductase member 3 (AKR7A3) OTW3GO4Y ARK73_HUMAN Gene/Protein Processing [11]
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [12]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Gene/Protein Processing [11]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Gene/Protein Processing [11]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Regulation of Drug Effects [13]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [11]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [14]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Gene/Protein Processing [15]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Gene/Protein Processing [15]
Catalase (CAT) OTHEBX9R CATA_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Atazanavir
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
MK-1439 DM215WE Minor Decreased metabolism of Atazanavir caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [16]
Fostemsavir DM50ILT Moderate Decreased metabolism of Atazanavir caused by Fostemsavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Dolutegravir DMCZGRE Moderate Decreased metabolism of Atazanavir caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Etravirine DMGV8QU Major Increased metabolism of Atazanavir caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [19]
Maraviroc DMTL94F Major Decreased metabolism of Atazanavir caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Raltegravir DMYURI6 Minor Decreased metabolism of Atazanavir caused by Raltegravir mediated inhibition of UGT. Human immunodeficiency virus disease [1C60-1C62] [21]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Atazanavir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Atazanavir due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [22]
Clindamycin DM15HL8 Moderate Decreased metabolism of Atazanavir caused by Clindamycin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [23]
Ivosidenib DM8S6T7 Major Decreased metabolism of Atazanavir caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [24]
Midostaurin DMI6E0R Major Decreased metabolism of Atazanavir caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [25]
Arn-509 DMT81LZ Moderate Increased metabolism of Atazanavir caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [26]
Gilteritinib DMTI0ZO Major Decreased metabolism of Atazanavir caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [27]
Oliceridine DM6MDCF Major Decreased metabolism of Atazanavir caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [28]
Ivabradine DM0L594 Major Decreased metabolism of Atazanavir caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [19]
Bepridil DM0RKS4 Major Decreased metabolism of Atazanavir caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [22]
Dronedarone DMA8FS5 Major Decreased metabolism of Atazanavir caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [19]
Nifedipine DMSVOZT Moderate Decreased metabolism of Atazanavir caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [22]
Bedaquiline DM3906J Moderate Decreased metabolism of Atazanavir caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [29]
Cilostazol DMZMSCT Major Decreased metabolism of Atazanavir caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [30]
Posaconazole DMUL5EW Moderate Decreased metabolism of Atazanavir caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [22]
Budesonide DMJIBAW Major Decreased metabolism of Atazanavir caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [31]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Atazanavir caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Atazanavir caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [19]
Rabeprazole DMMZXIW Major Decreased absorption of Atazanavir due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [19]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Atazanavir caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Cariprazine DMJYDVK Major Decreased metabolism of Atazanavir caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [32]
Erdafitinib DMI782S Major Decreased metabolism of Atazanavir caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [33]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Atazanavir caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Lapatinib DM3BH1Y Major Decreased metabolism of Atazanavir caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
HKI-272 DM6QOVN Major Decreased metabolism of Atazanavir caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
LY2835219 DM93VBZ Major Decreased metabolism of Atazanavir caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [36]
Tucatinib DMBESUA Moderate Decreased metabolism of Atazanavir caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Palbociclib DMD7L94 Major Decreased metabolism of Atazanavir caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [38]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Atazanavir caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Atazanavir caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
Atorvastatin DMF28YC Major Decreased metabolism of Atazanavir caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [39]
PF-04449913 DMSB068 Major Decreased metabolism of Atazanavir caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [40]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Atazanavir caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [41]
Revefenacin DMMP5SI Moderate Decreased clearance of Atazanavir due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [42]
Indacaterol DMQJHR7 Minor Decreased metabolism of Atazanavir caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [43]
Levomilnacipran DMV26S8 Major Decreased metabolism of Atazanavir caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [44]
Anisindione DM2C48U Moderate Decreased metabolism of Atazanavir caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [45]
Regorafenib DMHSY1I Moderate Decreased metabolism of Atazanavir caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [19]
Drospirenone DM1A9W3 Major Decreased metabolism of Atazanavir caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [19]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Atazanavir caused by Levonorgestrel mediated inhibition of UGT. Contraceptive management [QA21] [22]
Ulipristal DMBNI20 Minor Decreased metabolism of Atazanavir caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [30]
Mestranol DMG3F94 Moderate Decreased metabolism of Atazanavir caused by Mestranol mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [46]
Pasireotide DMHM7JS Moderate Increased risk of atrioventricular block by the combination of Atazanavir and Pasireotide. Cushing syndrome [5A70] [47]
Osilodrostat DMIJC9X Major Decreased metabolism of Atazanavir caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [30]
Ivacaftor DMZC1HS Major Decreased metabolism of Atazanavir caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [19]
MK-8228 DMOB58Q Moderate Decreased metabolism of Atazanavir caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [48]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Atazanavir caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [19]
Vilazodone DM4LECQ Major Decreased metabolism of Atazanavir caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [49]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Atazanavir caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [22]
Escitalopram DMFK9HG Minor Decreased metabolism of Atazanavir caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [50]
OPC-34712 DMHG57U Major Decreased metabolism of Atazanavir caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Clomipramine DMINRKW Moderate Decreased metabolism of Atazanavir caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [52]
Doxepin DMPI98T Moderate Decreased metabolism of Atazanavir caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [52]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Atazanavir caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [53]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Atazanavir due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [22]
Ospemifene DMC4GEI Moderate Decreased metabolism of Atazanavir caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [54]
Oestradiol valerate and dienogest DMZK0FQ Moderate Decreased metabolism of Atazanavir caused by Oestradiol valerate and dienogest mediated inhibition of CYP450 enzyme. Endometriosis [GA10] [46]
Cenobamate DM8KLU9 Moderate Increased metabolism of Atazanavir caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Atazanavir caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Phenobarbital DMXZOCG Moderate Increased metabolism of Atazanavir caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Atazanavir caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Cannabidiol DM0659E Minor Decreased metabolism of Atazanavir caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [30]
Bay 80-6946 DMLOS5R Major Decreased clearance of Atazanavir due to the transporter inhibition by Bay 80-6946. Follicular lymphoma [2A80] [55]
Tazemetostat DMWP1BH Major Decreased metabolism of Atazanavir caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [56]
Solifenacin DMG592Q Major Decreased metabolism of Atazanavir caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [19]
Mirabegron DMS1GYT Minor Decreased metabolism of Atazanavir caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [57]
Miconazole DMPMYE8 Moderate Decreased metabolism of Atazanavir caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [22]
Dexlansoprazole DM1DBV5 Major Decreased absorption of Atazanavir due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [19]
Ripretinib DM958QB Major Decreased metabolism of Atazanavir caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [19]
Sunitinib DMCBJSR Moderate Decreased metabolism of Atazanavir caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [19]
Avapritinib DMK2GZX Major Decreased metabolism of Atazanavir caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [30]
Colchicine DM2POTE Major Decreased metabolism of Atazanavir caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [58]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Atazanavir caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [26]
ABT-450 DMFW860 Major Decreased metabolism of Atazanavir caused by ABT-450 mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [59]
Simeprevir DMLUA9D Major Decreased metabolism of Atazanavir caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [19]
Telaprevir DMMRV29 Minor Increased metabolism of Atazanavir caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [19]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Atazanavir caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [19]
GS-9857 DMYU6P5 Major Decreased clearance of Atazanavir due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [22]
Rifapentine DMCHV4I Major Increased metabolism of Atazanavir caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [26]
Brentuximab vedotin DMWLC57 Moderate Decreased metabolism of Atazanavir caused by Brentuximab vedotin mediated inhibition of CYP450 enzyme. Hodgkin lymphoma [2B30] [30]
Rosuvastatin DMMIQ7G Major Decreased clearance of Atazanavir due to the transporter inhibition by Rosuvastatin. Hyper-lipoproteinaemia [5C80] [19]
BMS-201038 DMQTAGO Major Decreased metabolism of Atazanavir caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [19]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Atazanavir due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [30]
Aliskiren DM1BV7W Moderate Decreased metabolism of Atazanavir caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [47]
Levamlodipine DM92S6N Moderate Decreased metabolism of Atazanavir caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [22]
Tolvaptan DMIWFRL Major Decreased metabolism of Atazanavir caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [19]
Retapamulin DM9JXB7 Minor Decreased metabolism of Atazanavir caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [60]
Lesinurad DMUR64T Moderate Increased metabolism of Atazanavir caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [26]
TP-434 DM5A31S Minor Decreased metabolism of Atazanavir caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [61]
Suvorexant DM0E6S3 Major Decreased metabolism of Atazanavir caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [62]
Amobarbital DM0GQ8N Moderate Increased metabolism of Atazanavir caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [26]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Atazanavir caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [63]
ITI-007 DMUQ1DO Major Decreased metabolism of Atazanavir caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [64]
Eluxadoline DMYZ0P1 Major Decreased clearance of Atazanavir due to the transporter inhibition by Eluxadoline. Irritable bowel syndrome [DD91] [30]
Crizotinib DM4F29C Major Decreased metabolism of Atazanavir caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [19]
Brigatinib DM7W94S Major Decreased metabolism of Atazanavir caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [65]
Ceritinib DMB920Z Major Decreased metabolism of Atazanavir caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [19]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Atazanavir caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [66]
PF-06463922 DMKM7EW Major Decreased metabolism of Atazanavir caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [67]
Osimertinib DMRJLAT Major Decreased metabolism of Atazanavir caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [68]
Pralsetinib DMWU0I2 Major Decreased metabolism of Atazanavir caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [69]
Capmatinib DMYCXKL Major Decreased metabolism of Atazanavir caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [70]
Selpercatinib DMZR15V Major Decreased metabolism of Atazanavir caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [30]
Artemether DM48QOT Major Decreased metabolism of Atazanavir caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [19]
Halofantrine DMOMK1V Major Decreased metabolism of Atazanavir caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [71]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Atazanavir caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [19]
Idelalisib DM602WT Moderate Decreased metabolism of Atazanavir caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [72]
IPI-145 DMWA24P Major Decreased metabolism of Atazanavir caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [73]
Acalabrutinib DM7GCVW Major Decreased metabolism of Atazanavir caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [74]
Ibrutinib DMHZCPO Major Decreased metabolism of Atazanavir caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [75]
Ponatinib DMYGJQO Major Decreased metabolism of Atazanavir caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [19]
Arry-162 DM1P6FR Moderate Decreased clearance of Atazanavir due to the transporter inhibition by Arry-162. Melanoma [2C30] [19]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Atazanavir caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [76]
Selumetinib DMC7W6R Major Decreased metabolism of Atazanavir caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [77]
LGX818 DMNQXV8 Major Decreased metabolism of Atazanavir caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [78]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Atazanavir caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [19]
Danazol DML8KTN Moderate Decreased metabolism of Atazanavir caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [22]
Ubrogepant DM749I3 Major Decreased metabolism of Atazanavir caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [79]
Rimegepant DMHOAUG Moderate Decreased metabolism of Atazanavir caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [80]
Exjade DMHPRWG Moderate Decreased metabolism of Atazanavir caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [81]
Flibanserin DM70DTN Major Decreased metabolism of Atazanavir caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [82]
Panobinostat DM58WKG Moderate Decreased metabolism of Atazanavir caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [83]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Atazanavir and Siponimod. Multiple sclerosis [8A40] [19]
Fingolimod DM5JVAN Moderate Increased risk of atrioventricular block by the combination of Atazanavir and Fingolimod. Multiple sclerosis [8A40] [84]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Atazanavir and Ozanimod. Multiple sclerosis [8A40] [85]
Deflazacort DMV0RNS Major Decreased metabolism of Atazanavir caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [30]
Fedratinib DM4ZBK6 Major Decreased metabolism of Atazanavir caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [30]
Nilotinib DM7HXWT Major Decreased metabolism of Atazanavir caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [19]
Ruxolitinib DM7Q98D Major Decreased metabolism of Atazanavir caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [86]
Dasatinib DMJV2EK Major Decreased metabolism of Atazanavir caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [19]
Vorapaxar DMA16BR Major Decreased metabolism of Atazanavir caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [19]
Netupitant DMEKAYI Minor Decreased metabolism of Atazanavir caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [87]
Entrectinib DMMPTLH Major Decreased metabolism of Atazanavir caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [19]
Orlistat DMRJSP8 Moderate Altered absorption of Atazanavir caused by Orlistat. Obesity [5B80-5B81] [88]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Atazanavir caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [89]
S-297995 DM26IH8 Moderate Decreased metabolism of Atazanavir caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [30]
Olaparib DM8QB1D Major Decreased metabolism of Atazanavir caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [19]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Atazanavir caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [90]
Istradefylline DM20VSK Major Decreased metabolism of Atazanavir caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [91]
Pimavanserin DMR7IVC Major Decreased metabolism of Atazanavir caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [92]
Abametapir DM2RX0I Moderate Decreased metabolism of Atazanavir caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [93]
Lefamulin DME6G97 Major Decreased clearance of Atazanavir due to the transporter inhibition by Lefamulin. Pneumonia [CA40] [94]
Ergonovine DM0VEC1 Major Decreased metabolism of Atazanavir caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [95]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Atazanavir caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [96]
ABIRATERONE DM8V75C Minor Decreased metabolism of Atazanavir caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [97]
Enzalutamide DMGL19D Moderate Increased metabolism of Atazanavir caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [26]
Darolutamide DMV7YFT Moderate Decreased metabolism of Atazanavir caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [98]
Silodosin DMJSBT6 Major Decreased metabolism of Atazanavir caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [19]
Ambrisentan DMD1QXW Minor Decreased metabolism of Atazanavir caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [99]
Riociguat DMXBLMP Moderate Decreased metabolism of Atazanavir caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [19]
Everolimus DM8X2EH Major Decreased clearance of Atazanavir due to the transporter inhibition by Everolimus. Renal cell carcinoma [2C90] [19]
Axitinib DMGVH6N Major Decreased metabolism of Atazanavir caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [19]
Temsirolimus DMS104F Major Increased metabolism of Atazanavir caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [19]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Atazanavir caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [100]
Upadacitinib DM32B5U Major Decreased metabolism of Atazanavir caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [101]
Tofacitinib DMBS370 Major Decreased metabolism of Atazanavir caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [19]
Dexamethasone DMMWZET Moderate Decreased metabolism of Atazanavir caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [19]
Quetiapine DM1N62C Major Decreased metabolism of Atazanavir caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [102]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Atazanavir caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [103]
Iloperidone DM6AUFY Major Decreased metabolism of Atazanavir caused by Iloperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [104]
Pimozide DMW83TP Major Decreased metabolism of Atazanavir caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [19]
Avanafil DM75CXN Major Decreased metabolism of Atazanavir caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [19]
Voxelotor DMCS6M5 Major Decreased metabolism of Atazanavir caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [105]
LDE225 DMM9F25 Major Decreased metabolism of Atazanavir caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [106]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Atazanavir caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [30]
Larotrectinib DM26CQR Major Decreased metabolism of Atazanavir caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [19]
PDX-101 DM6OC53 Moderate Decreased metabolism of Atazanavir caused by PDX-101 mediated inhibition of UGT. Solid tumour/cancer [2A00-2F9Z] [107]
Docetaxel DMDI269 Major Decreased metabolism of Atazanavir caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [108]
Trabectedin DMG3Y89 Major Decreased metabolism of Atazanavir caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [19]
Armodafinil DMGB035 Moderate Increased metabolism of Atazanavir caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [109]
Taxol DMUOT9V Major Decreased metabolism of Atazanavir caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [110]
Pitolisant DM8RFNJ Moderate Increased metabolism of Atazanavir caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [30]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Atazanavir caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [19]
Fostamatinib DM6AUHV Major Decreased metabolism of Atazanavir caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [111]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Atazanavir due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [90]
Apixaban DM89JLN Moderate Decreased metabolism of Atazanavir caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [30]
Brilinta DMBR01X Major Decreased metabolism of Atazanavir caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [19]
Saxagliptin DMGXENV Moderate Decreased metabolism of Atazanavir caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [30]
Elagolix DMB2C0E Major Decreased metabolism of Atazanavir caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [112]
Fluticasone DMGCSVF Major Decreased metabolism of Atazanavir caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [113]
Betrixaban DM2C4RF Moderate Accelerated clearance of Atazanavir due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [114]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Atazanavir caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [19]
⏷ Show the Full List of 181 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Atazanavir 150 mg capsule 150 mg Oral Capsule Oral
Atazanavir 200 mg capsule 200 mg Oral Capsule Oral
Atazanavir 300 mg capsule 300 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016 Apr;99(4):363-9. doi: 10.1002/cpt.269. Epub 2015 Nov 9.
7 Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
8 Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
9 Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
10 In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005 Nov;33(11):1729-39.
11 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
12 Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
13 Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats. Reprod Toxicol. 2018 Aug;79:57-65. doi: 10.1016/j.reprotox.2018.05.008. Epub 2018 May 30.
14 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
15 Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
16 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
17 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
18 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
19 Cerner Multum, Inc. "Australian Product Information.".
20 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
21 Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
22 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
23 Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
24 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
25 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
26 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
27 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
28 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
29 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
30 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
32 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
33 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
34 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
35 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
36 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
37 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
38 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
40 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
41 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
42 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
43 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
44 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
45 Hermans JJ, Thijssen HH "Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics." Br J Pharmacol 110 (1993): 482-90. [PMID: 8220911]
46 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
47 Canadian Pharmacists Association.
48 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
49 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
50 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
51 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
52 Eap CB, Bender S, Gastpar M, et al "Steady state plasma levels of the enantiomers of trimipramine and its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients." Ther Drug Monit 22 (2000): 209-14. [PMID: 10774635]
53 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
54 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
55 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
56 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
57 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
58 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
59 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
60 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
61 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
62 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
63 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
64 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
65 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
66 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
67 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
68 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
69 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
70 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
71 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
72 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
73 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
74 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
75 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
76 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
77 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
78 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
79 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
80 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
81 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
82 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
83 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
84 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
85 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
86 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
87 Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
88 MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.".
89 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
90 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
91 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
92 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
93 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
94 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
95 Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8. [PMID: 12618710]
96 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
97 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
98 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
99 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
100 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
101 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
102 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
103 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
104 Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
105 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
106 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
107 Product Information. Beleodaq (belinostat). Spectrum Pharmaceuticals Inc, Irvine, CA.
108 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
109 Barry M, Gibbons S, Back D, Mulcahy F "Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations." Clin Pharmacokinet 32 (1997): 194-209. [PMID: 9084959]
110 Bundow D, Aboulafia DM "Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma." Am J Clin Oncol 27 (2004): 81-4. [PMID: 14758138]
111 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
112 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
113 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
114 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]